Clinical Trial Update: Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease [Phase 4]

View source ↗

Summary

Phase 4 study updating on adalimumab to lower cardiovascular risk in rheumatoid arthritis patients with well-controlled joint disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Rheumatoid Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: Jonathan Graf | Conditions: Rheumatoid Arthritis, Cardiovascular Disease | Phase 4 | Status: COMPLETED